Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P675: The relationship between gender, severity of disease, treatment type, and employment outcome in patients with inflammatory bowel disease in Israel

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Naftali*1,2, A. Ein Dor Abarbanel3, N. Ruhimovich2, A. Bar-Gil Shitrit4, F. Sklerovsky-Benjaminov1,2, H. Shirin1,3, S. Matalon1,3, T. Ziv Baran5, E. Broide1,3

1Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel, 2Meir Hospital, Gastroenterology and Liver disease, Kfar Saba, Israel, 3Assaf Harofeh, The Kamila Gonczarowski Institute for Gastroenterology and Liver Diseases, Zerifin, Israel, 4Shaare Zedek Medical Center, Gastroenterology institute, Jerusalem, Israel, 5Sackler Faculty of Medicine Tel Aviv University, Department of Epidemiology and Preventive Medicine, Tel aviv, Israel

P676: The impact to disease activity, iron and vitamin D deficiency on fatigue in IBD patients

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Atanassova*1, A. Georgieva1, D. Gerova2, M. Todorova2

1Medical University Varna, Clinic of Hepatogastroenterology, St. Marina University Hospital, Varna, Bulgaria, 2Medical University Varna, Department of General Medicine and Clinical Laboratory, Varna, Bulgaria

P677: Effect of late faecal loss of infliximab on treatment response of inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

F. AlborziAvanaki*1, H. Rezvan1, N. Ebrahimi Daryani1, N. Ale Taha1

1Tehran university ofMedical Sciences, Tehran, Iran, Islamic Republic of

P678: Treatment of moderate to severe UC patients with new 5ASA tablets

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Laoun*1, R. Hofmann2

1Tillotts Pharma AG, Medical Affairs, Rheinfelden, Switzerland, 2Tillotts Pharma, Medicines Management, Rheinfelden, Switzerland

P679: Development of a novel auto-injector of subcutaneous CT-P13 infliximab: Phase I randomised, open-label, single-dose trial to compare the pharmacokinetics and safety to pre-filled syringe in healthy subjects

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Schreiber*1, S. Ben-Horin2, B. D. Ye3, R. Westhovens4, D. H. Yoo5, S. J. Lee6, J. H. Suh6, J. H. Byeon6, W. Reinisch7

1University Hospital Schleswig-Holstein, Kiel, Germany, 2Sheba Medical Center, Tel Hashomer, Israel, 3Asan Medical Center, Seoul, South Korea, 4University Hospital KU Leuven, Leuven, Belgium, 5Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 6Celltrion, Inc., Incheon, South Korea, 7Medical University Vienna, Vienna, Austria

P680: Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn’s disease: results from IM-UNITI long-term extension through 2 years

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Ghosh*1, B. C. Kramer2, C. Gasink2, D. Jacobstein3, O. J. Adedokun3, L-L. Gao3, P. Rutgeerts4, B. E. Sands5

1University of Birmingham, Birmingham, UK, 2Janssen Scientific Affairs, LLC, Horsham, USA, 3Janssen Research and Development, LLC, Spring House, USA, 4University Hospital Gasthuisberg, Leuven, Belgium, 5Icahn School of Medicine at Mount Sinai, New York, USA

P681: Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies

ECCO '19 Copenhagen

Year: 2019
Authors:

B. E. Sands*1, C. Han2, H. Zhang3, J. Johanns3, P. Szapary3, C. Marano3, R. W. Leong4,5, S. Danese6

1Icahn School of Medicine at Mount Sinai, New York, USA, 2Janssen Global Services, LLC, Malvern, USA, 3Janssen Research & Development, LLC, Spring House, USA, 4Concord Hospital, Sydney, Australia, 5Macquarie University Hospital, Sydney, Australia, 6Humanitas Research Hospital, Milan, Italy